Preclinical study design for evaluation of stem cell-derived cellular therapy products: a pathologist's perspective
Related Experiment Video
Updated: Apr 21, 2026
High Throughput Characterization of Adult Stem Cells Engineered for Delivery of Therapeutic Factors for Neuroprotective Strategies
Published on: January 4, 2015
Julia F M Baker1, Basel T Assaf2
1Charles River Pathology Associates, Frederick, Maryland, USA julia.baker@crl.com.
Abstract:
Despite-or perhaps because of-the rapid expansion of interest in stem cell-derived cellular therapy products, relatively few guidelines have been published to assist in the design of scientifically sound preclinical studies. The field is complex and wide ranging, and of necessity regulators tend to treat each project on a case by case basis. One of the core tenets remains the need to retain all tissues from the study, thereby allowing for further analysis of tissues should unexpected effects be seen in clinical studies; attempts to comply with this may result in an unmanageable financial burden. Judicious input from the pathologist at the earliest stages of study design may not only improve the scientific integrity of the study but also help to mitigate some of the cost. Careful animal selection, the development of robust cell markers, and justifiable triage of tissues based on phased tissue examination can all be discussed with the regulatory authorities at pre-pre-investigational new drug (IND) and pre-IND meetings to achieve optimal study design.
Insights
Designing preclinical studies for stem cell therapies requires careful planning. Pathologist involvement and strategic tissue examination can improve scientific rigor and manage costs for these complex cellular therapy products.
Area of Science:
- Regenerative Medicine
- Preclinical Study Design
- Stem Cell Therapy
Background:
- Growing interest in stem cell-derived cellular therapy products necessitates clear preclinical study guidelines.
- Current regulatory approaches often treat projects case-by-case due to the field's complexity.
- Retaining all tissues for potential future analysis can lead to significant financial burdens.
Purpose of the Study:
- To provide guidance on designing scientifically sound preclinical studies for stem cell therapies.
- To explore strategies for mitigating costs associated with comprehensive tissue retention.
- To emphasize the importance of early pathologist consultation in study design.
Main Methods:
- Discussing strategies for careful animal selection.
- Highlighting the development of robust cell markers for tracking.
- Proposing justifiable triage of tissues based on phased examination.
- Recommending engagement with regulatory authorities at pre-pre-Investigational New Drug (IND) and pre-IND meetings.
Main Results:
- Early pathologist input can enhance scientific integrity.
- Strategic tissue examination and triage can help manage study costs.
- Collaborative discussions with regulatory bodies can optimize study design.
Conclusions:
- Optimizing preclinical study design for stem cell therapies is crucial for regulatory success.
- Integrating pathological expertise early can improve study outcomes and cost-effectiveness.
- Proactive engagement with regulatory agencies is key to navigating complex study requirements.
